STOCK TITAN

PicoCELA (PCLA) sells $5M preferred stock and grants investor strong control rights

(Neutral)
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

PicoCELA Inc. entered into a Class A Preferred Share Purchase Agreement with an institutional investor to issue and sell 20,000,000 Class A preferred shares at $0.25 per share for $5,000,000 gross proceeds. Univest Securities acted as placement agent, earning a 7.0% cash fee plus up to $150,000 accountable and 1.0% non-accountable expenses, and received an 18‑month right of first refusal on future financings and certain transactions.

Net proceeds of approximately $4,449,975 will fund mesh Wi‑Fi manufacturing costs and U.S. listing maintenance. Each Preferred Share converts into one Common Share, or into two Common Shares if the Common Share or ADS price is at or below $0.50 for 20 consecutive trading days, and carries one vote. As of July 16, 2026, PicoCELA had 9,613,805 Common Shares and 20,000,000 Preferred Shares outstanding, totaling 29,613,805 voting rights. While the investor holds more than 50% of voting rights, it has consent rights over new securities issuances, significant transactions above $250,000, and Board matters, including designating a representative director. Following payment for the Preferred Shares, two investor‑linked nominees, Lim Kien Leong and Jong Han Rey Foo, joined the six‑member Board, of which two directors are Nasdaq‑independent.

Positive

  • None.

Negative

  • None.

Filing Explained

The July 16, 2026 closing completed the issuance in a Rule 506 private transaction exempt from Securities Act registration and conducted without general solicitation; it was an issuance of securities, not a registered offering.

Preferred Shares Issued 20,000,000 shares Class A preferred shares sold to a fundamental institutional investor
Offering Price $0.25 per share Price per Class A preferred share in the July 14, 2026 agreement
Gross Proceeds $5,000,000 Total proceeds from the sale of 20,000,000 Class A preferred shares
Net Proceeds $4,449,975 Approximate net cash received on July 16, 2026 after fees and expenses
Placement Fee 7.0% Cash fee on gross cash proceeds payable to Univest Securities
Accountable Expenses Cap $150,000 Maximum accountable expenses reimbursable to Univest
Total Voting Rights 29,613,805 Voting rights outstanding as of July 16, 2026
Asset Consent Threshold $250,000 Value above which asset transfers require investor consent during Holding Period
Rule 506 of Regulation D regulatory
"exempt from the registration requirements... under Rule 506 of Regulation D"
Rule 506 of Regulation D is a U.S. Securities and Exchange Commission exemption that lets companies sell securities privately without registering them with the SEC, similar to a private party invitation rather than a public auction. It matters to investors because it determines how much information they’ll receive, who can buy (accredited vs. non-accredited), whether public advertising is allowed, and how easily the investment can be resold — all factors that affect risk, transparency and liquidity.
accredited investor regulatory
"The Investor represented... that it is an accredited investor within the meaning of Rule 501(a)"
An accredited investor is an individual or entity that meets certain financial criteria, such as having a high income or significant net worth, allowing them to invest in private or less regulated investment opportunities. This status matters because it grants access to investments that are often riskier or less available to the general public, reflecting a higher level of financial knowledge or resources.
American depositary share financial
"each such Common Share will be represented by one American depositary share (the “ADS”)"
An American Depositary Share (ADS) is a U.S.-listed certificate that represents a specified number of shares in a foreign company, held by a custodian bank; it works like a receipt that allows U.S. investors to buy and trade foreign equity on American exchanges without dealing with another country’s markets. Investors care because ADSs make foreign stocks easier to access, improve liquidity and settlement in dollars, and can affect dividend payments, voting rights and regulatory oversight compared with buying the underlying foreign shares directly.
right of first refusal financial
"Univest also holds an exclusive right of first refusal (the “ROFR”) for 18 months"
A right of first refusal gives an existing shareholder or party the chance to buy an asset or shares before the owner can sell them to someone else. Think of it like being offered the first option to buy a house when the owner decides to sell; it matters to investors because it can limit who can acquire a stake, slow or block transactions, and affect the price and liquidity of an investment by restricting open-market sales or new buyers.
extraordinary general meeting of shareholders regulatory
"the results of the Company’s extraordinary general meeting of shareholders (the “EGM”)"
A meeting called by a company outside its regular annual meeting to address urgent or special matters that cannot wait until the next scheduled meeting. Investors attend or vote to decide on actions such as major deals, leadership changes, capital-raising, or rule changes; think of it as an emergency board meeting where shareholders have a direct say and the outcomes can quickly change a company’s strategy, ownership stakes, or financial prospects.
representative director regulatory
"the Board is required to elect a director designated by the Investor as a representative director"
A representative director is a company leader who is legally authorized to act and sign agreements on behalf of the corporation, similar to a captain who can steer the ship and make binding calls for the whole crew. Investors care because this person’s decisions, public statements, and legal responsibility directly affect the company’s strategy, risk exposure and reputation, and their authority determines who can commit the company to deals or liabilities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What capital did PicoCELA (PCLA) raise and on what terms?

PicoCELA raised $5,000,000 by issuing 20,000,000 Class A preferred shares at $0.25 each to an institutional investor. The preferred shares carry one vote per share and are initially convertible into one common share, with an enhanced conversion if the share price falls.

How will PicoCELA (PCLA) use the net proceeds from this offering?

PicoCELA plans to use approximately $4,449,975 in net proceeds for mesh Wi‑Fi product manufacturing costs and maintenance of its U.S. listing. These uses focus on supporting core product deployment and sustaining access to U.S. capital markets.

What are the conversion features of PicoCELA (PCLA) Class A preferred shares?

Each Class A preferred share converts into one common share, represented by an ADS upon deposit. If the common share or ADS price is $0.50 or less for 20 consecutive trading days, each preferred share instead becomes convertible into two common shares, subject to customary adjustments.

What are PicoCELA (PCLA)’s share and voting rights totals after the transaction?

As of July 16, 2026, PicoCELA had 9,613,805 common shares and 20,000,000 preferred shares outstanding, for a total of 29,613,805 voting rights. Each preferred share provides one vote, giving the new investor substantial influence over shareholder decisions.

What compensation and rights did Univest receive in PicoCELA (PCLA)’s financing?

Univest earns a 7.0% cash fee on gross proceeds, up to $150,000 in accountable expenses, and 1.0% non‑accountable expenses. It also holds an 18‑month right of first refusal to act as investment banker on future financings and certain strategic transactions.

Which new directors joined PicoCELA (PCLA)’s board in connection with the offering?

Upon full payment for the preferred shares on July 16, 2026, Lim Kien Leong, co‑founder and CEO of TranSwap, and Jong Han Rey Foo, a Singapore corporate lawyer, became directors. The Board now has six members, including two Nasdaq‑independent directors.

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of July 2026

 

Commission File Number: 001-42470

 

PicoCELA Inc.

 

2-34-5 Ningyocho, SANOS Building, Nihonbashi

Chuo-ku, Tokyo 103-0013 Japan

(Address of Principal Executive Office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F ☒ Form 40-F ☐

 

 

 

 
 

 

Entry into Material Definitive Agreement and Issuance of PicoCELA Inc.’s Class A Preferred Shares

 

On July 14, 2026, PicoCELA Inc., a Japanese joint-stock corporation with limited liability (the “Company”), entered into a Class A Preferred Share Purchase Agreement (the “Purchase Agreement”) with a certain fundamental institutional investor (the “Investor”). Pursuant to the Purchase Agreement, the Company agreed to issue and sell 20,000,000 Class A preferred shares of the Company (each a “Preferred Share,” and collectively, the “Preferred Shares”) at the price of $0.25, for gross proceeds of $5,000,000 (the “Offering”).

 

The Company engaged Univest Securities, LLC (“Univest”) as the Company’s placement agent and financial advisor for the Offering, pursuant to an engagement letter between Univest and the Company (the “Engagement Letter”), dated April 7, 2026. Pursuant to the Engagement Letter, the Company agreed to pay Univest a cash fee equal to 7.0% of the gross cash proceeds of the Offering and reimburse up to $150,000 for accountable expenses and up to 1.0% of the actual amount of the Offering for non-accountable expenses. Univest is also entitled to the same compensation set forth above on any equity, debt, or equity derivative instruments sold to any investor actually introduced by Univest to the Company during the engagement period, if such a financing is consummated within 12 months from the closing date of the Offering.

 

Univest also holds an exclusive right of first refusal (the “ROFR”) for 18 months after the Offering’s closing to serve as the Company’s investment banker on any underwritten or private securities offering, as well as any majority sale, acquisition, or merger transaction.

 

On July 16, 2026, upon the Company’s receipt of the net proceeds of approximately $4,449,975, after deducting advisory fees and expense payable to Univest and other offering expenses, the Investor obtained 20,000,000 Preferred Shares from the Company pursuant to the Purchase Agreement. The Company intends to use the net cash proceeds from the Offering for (i) the manufacturing cost of mesh wi-fi products, and (ii) the maintenance fee for the Company’s U.S. listing.

 

The Preferred Shares are convertible at the Investor’s election into one common share of the Company (each, a “Common Share,” and, collectively, the “Common Shares,” and each such Common Share will be represented by one American depositary share (the “ADS”) upon the Investor’s deposit of such Common Share with the depositary and the issuance of such ADS by the depositary) per Preferred Share, subject to customary adjustments for stock splits, reverse stock splits and similar events. If the price of the Common Shares, or the ADS price equivalent, is $0.50 or less for 20 consecutive trading days, each Preferred Share becomes convertible into two Common Shares. Each Preferred Share is entitled to one vote on all matters submitted to shareholders.

 

The Purchase Agreement provides, among other things, that: (i) the Investor has the right, as a shareholder and subject to applicable Japanese law, to propose the appointment and replacement of directors to the Company’s board of directors (the “Board”); (ii) the Board may not propose an adjustment to the size of the Board without Investor’s prior consent; (iii) the Company and the Board shall not issue any equity, equity derivatives, equity convertible instruments, or equity compensation for directors and employees (the “Japanese Equity Securities”) without the Investor’s prior consent until the Company amends its articles of incorporation to require a shareholders meeting to issue the Japanese Equity Securities; (iv) during the period when the Investor holds more than 50% of the Company’s voting rights (the “Holding Period”), the Company may not, without the Investor’s consent, issue Common Shares, ADSs, preferred shares or other securities; (v) during the Holding Period, the Board is required to elect a director designated by the Investor as a representative director with sole authority to execute agreements on behalf of the Company; and (vi) during the Holding Period, the Company may not, without the Investor’s prior written consent, sell, transfer, assign, license, pledge, encumber, dispose of or otherwise convey any assets, intellectual property, cash or other property worth more than $250,000, except for the ordinary course of operations.

 

As of July 16, 2026, there were 9,613,805 Common Shares and 20,000,000 Preferred Shares issued and outstanding, representing a total of 29,613,805 voting rights exercisable at a general meeting of shareholders.

 

The Offering was exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), pursuant to the exemption for transactions by an issuer not involving any public offering under Rule 506 of Regulation D promulgated under the Securities Act (“Regulation D”). The Investor represented to the Company that it is an accredited investor within the meaning of Rule 501(a) of Regulation D and that it was acquiring the securities in the Offering for investment only and not with a view to the resale or distribution of any part thereof in violation of the Securities Act. The securities issued in the Offering were offered without any general solicitation by the Company or its representatives.

 

 
 

 

The representations, warranties, and covenants contained in the Purchase Agreement were made solely for the benefit of the parties to the Purchase Agreement and may be subject to limitations agreed upon by the contracting parties. In addition, such representations, warranties, and covenants (i) are intended as a way of allocating the risk between the parties to the Purchase Agreement and not as statements of fact, and (ii) may apply standards of materiality in a way that is different from what may be viewed as material by shareholders of, or other investors in, the Company. Accordingly, the Purchase Agreement is filed with this report only to provide investors with information regarding the terms of transaction, and not to provide investors with any other factual information regarding the Company. Shareholders should not rely on the representations, warranties, and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of the Company. Moreover, information concerning the subject matter of the representations and warranties may change after the date of the Purchase Agreement, which subsequent information may or may not be fully reflected in public disclosures.

 

The Purchase Agreement is filed as Exhibit 99.1, and such document is incorporated herein by reference. The foregoing is only a brief description of the material terms of the Purchase Agreement and does not purport to be a complete description of the rights and obligations of the parties thereunder and is qualified in its entirety by reference to such exhibit.

 

Appointment of the Company’s Directors

 

Reference is made to the report on Form 6-K dated July 14, 2026, announcing the results of the Company’s extraordinary general meeting of shareholders (the “EGM”) and common stock shareholders meeting held on June 18, 2026. The EGM approved, among others, the election of Mr. Lim Kien Leong and Mr. Jong Han Rey Foo as the Company’s directors who are not members of audit and supervisory committee, subject to (i) the approval of the issuance of Preferred Shares by third-party allotment, which approval was obtained at the EGM, and (ii) the complete payment for the Preferred Shares.

 

Since the payment of the Preferred Shares was completed on July 16, 2026, the election of Mr. Lim Kien Leong and Mr. Jong Han Rey Foo as the Company’s directors became effective on July 16, 2026.

 

Mr. Lim Kien Leong, aged 37, is a co-founder and chief executive officer of TranSwap Private Limited (“TranSwap”), a Singaporean company, Mr. Leong was served as the Chief Legal Officer of TranSwap and was responsible for all of the company’s legal and regulatory issues, ensuring the company remained compliant with relevant authorities’ regulations. Lim Kien Leong graduated from the University of Sydney with his Bachelor of Commerce and Bachelor of Laws degrees.

 

Mr. Jong Han Rey Foo, aged 59, is a partner at KSCGP Juris LLP in Singapore. He was admitted to the Singapore Bar in 1992 and has been practicing law for 24 years. Mr. Foo has been practicing corporate law, and his present areas of practice include conveyancing, corporate law and civil litigation. Mr. Jong Han Rey Foo obtained an LL.B. from the University of Buckingham in 1990 and an LL.M. in Corporate and Commercial Laws from Queen Mary College, University of London in 1991.

 

There are no family relationships between the two directors and the other director or executive officer of the Company. The election of Mr. Lim Kien Leong and Mr. Jong Han Rey Foo was in connection with the Offering pursuant to the Purchase Agreement.

 

As of the date of this report, the Board is comprised of six directors, the two of which (Mr. Yoshinari Noguchi and Ms. Mutsuko Oba) satisfy the “independence” requirements of the Nasdaq listing rules and Rule 10A-3 under the Exchange Act.

 

Forward-Looking Statements

 

This report on Form 6-K may contain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. This report on Form 6-K also includes express and implied forward-looking statements regarding the Company’s current expectations, estimates, opinions and beliefs that are not historical facts. Such forward-looking statements may be identified by words such as “believes,” “expects,” “endeavors,” “anticipates,” “intends,” “plans,” “estimates,” “projects,” “should” and “objective” and the negative and variations of such words and similar words. These statements are made on the basis of current knowledge and, by their nature, involve numerous assumptions and uncertainties. Nothing set forth herein should be regarded as a representation, warranty or prediction that the Company will achieve or is likely to achieve any particular future result. Actual results may differ materially from those indicated in the forward-looking statements because the realization of those results is subject to many risks and uncertainties, including risks and uncertainties identified under the heading “Risk Factors” in the Company’s Annual Report on Form 20-F for the fiscal year ended September 30, 2025 and other information the Company has or may file with the U.S. Securities and Exchange Commission. Forward-looking statements contained in this report on Form 6-K are made as of the date of this report on Form 6-K, and the Company undertakes no duty to update such information except as required under applicable law.

 

Exhibit Index

 

Exhibit No.   Description
4.1   Class A Preferred Shares Purchase Agreement, dated as of July 14, 2026

 

 
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  PicoCELA Inc.
     
Date: July 27, 2026 By: /s/ Hiroshi Furukawa
  Name: Hiroshi Furukawa
  Title: Chairman, Chief Technology Officer, and Representative Director

 

 

 

Filing Exhibits & Attachments

1 document

Other Documents